Relevant clinical trials demonstrating efficacy of immune checkpoint inhibitors and BRAF kinase inhibitors and MEK kinase inhibitors (BRAF/MEK inhibitors) in unresectable/metastatic melanoma. The gene discussed is MAP2K7; the disease is metastatic melanoma.